Universal Beteiligungs und Servicegesellschaft mbH Has $10.16 Million Holdings in Guardant Health, Inc. $GH

Universal Beteiligungs und Servicegesellschaft mbH increased its position in shares of Guardant Health, Inc. (NASDAQ:GH) by 25.0% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 195,186 shares of the company’s stock after buying an additional 39,038 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Guardant Health were worth $10,157,000 at the end of the most recent reporting period.

A number of other institutional investors have also bought and sold shares of GH. Signaturefd LLC grew its holdings in Guardant Health by 50.5% during the 2nd quarter. Signaturefd LLC now owns 635 shares of the company’s stock worth $33,000 after acquiring an additional 213 shares during the period. American Century Companies Inc. grew its stake in Guardant Health by 0.3% during the first quarter. American Century Companies Inc. now owns 104,206 shares of the company’s stock worth $4,439,000 after purchasing an additional 282 shares during the period. IFP Advisors Inc increased its holdings in Guardant Health by 120.1% in the second quarter. IFP Advisors Inc now owns 612 shares of the company’s stock worth $33,000 after purchasing an additional 334 shares in the last quarter. HighTower Advisors LLC increased its holdings in Guardant Health by 0.9% in the first quarter. HighTower Advisors LLC now owns 51,107 shares of the company’s stock worth $2,177,000 after purchasing an additional 469 shares in the last quarter. Finally, PNC Financial Services Group Inc. lifted its stake in Guardant Health by 25.6% in the first quarter. PNC Financial Services Group Inc. now owns 2,638 shares of the company’s stock valued at $112,000 after buying an additional 537 shares during the period. Institutional investors own 92.60% of the company’s stock.

Insider Transactions at Guardant Health

In other news, insider John G. Saia sold 8,996 shares of the company’s stock in a transaction on Friday, November 7th. The shares were sold at an average price of $96.25, for a total value of $865,865.00. Following the completion of the sale, the insider owned 43,172 shares in the company, valued at $4,155,305. This represents a 17.24% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Medina Manuel Hidalgo sold 1,500 shares of the firm’s stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $95.19, for a total transaction of $142,785.00. Following the transaction, the director directly owned 815 shares in the company, valued at $77,579.85. The trade was a 64.79% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 313,045 shares of company stock worth $18,984,897 in the last quarter. 6.10% of the stock is currently owned by corporate insiders.

Guardant Health Stock Performance

Shares of GH opened at $99.55 on Thursday. The firm has a market capitalization of $12.55 billion, a P/E ratio of -31.01 and a beta of 1.56. Guardant Health, Inc. has a 52 week low of $29.91 and a 52 week high of $105.27. The stock has a 50 day moving average price of $73.06 and a two-hundred day moving average price of $57.79.

Guardant Health (NASDAQ:GH) last announced its earnings results on Wednesday, October 29th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.09. During the same period in the previous year, the firm posted ($0.88) EPS. The firm’s revenue was up 38.5% compared to the same quarter last year. Guardant Health has set its FY 2025 guidance at EPS. On average, equities analysts forecast that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on GH shares. Wells Fargo & Company started coverage on shares of Guardant Health in a research report on Monday, September 22nd. They set an “overweight” rating and a $72.00 price objective for the company. UBS Group lifted their price target on shares of Guardant Health from $80.00 to $110.00 and gave the company a “buy” rating in a research note on Thursday, October 30th. Canaccord Genuity Group set a $100.00 price objective on shares of Guardant Health in a report on Thursday, October 30th. Evercore ISI raised their target price on Guardant Health from $68.00 to $90.00 and gave the company an “outperform” rating in a research note on Thursday, October 30th. Finally, Raymond James Financial upped their price target on Guardant Health from $59.00 to $61.00 and gave the stock an “outperform” rating in a research note on Thursday, July 31st. Twenty-three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Guardant Health has a consensus rating of “Moderate Buy” and a consensus price target of $77.14.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.